APA (7th ed.) Citation

Seneviratne, S., Erglis, A., Walters, D., Whitbourn, R., Layland, J., Stewart, J., . . . Meredith, I. (2017). TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study. Journal of the American College of Cardiology, 70(18), B342. https://doi.org/10.1016/j.jacc.2017.09.1054

Chicago Style (17th ed.) Citation

Seneviratne, Sujith, et al. "TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study." Journal of the American College of Cardiology 70, no. 18 (2017): B342. https://doi.org/10.1016/j.jacc.2017.09.1054.

MLA (9th ed.) Citation

Seneviratne, Sujith, et al. "TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study." Journal of the American College of Cardiology, vol. 70, no. 18, 2017, p. B342, https://doi.org/10.1016/j.jacc.2017.09.1054.